PBLA - Earnings call transcript Q1 2021 | Panbela Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings and welcome to Panbela Therapeutics First Quarter 2021 Earnings Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host James Carbonara with Hayden IR

James Carbonara

you. Thank welcome quarter again earnings Panbela's to once XXXX first call. And Jennifer on Chief Executive the me Simpson, Financial call Horvath, With Sue are Chief to Officer Officer. and

filed in that to I from today's such not as on are SEC. those made company's to subsequently on in that the and may the statements Significant not implied Simpson, does Before date, any could Any other call obligation statements. by company facts quarterly as that on developments. the over expressed of statements looking this supplemented form the update forward-looking statements and the to reports please call company call or turn historical are note on XX-Q, reports report or any the subsequent supplement forward forward differ risks undertake and statements well are be form has made that reflect cause made this results to detailed with filed Dr. annual looking XX-K as in uncertainties only actual

Simpson, to like Jennifer to Dr. please of Panbela. call Jennifer, over I'd turn proceed. the Now CEO

Jennifer Simpson

follow recent Thank accomplishments. touching on open it and call you Sue Q&A. I'll by financial for first review quarter will then everyone the the of a we will joining. begin up then the And with significant results. up for

be clinical patients the and treatment or indications. February of of communication when with with of trial disturbance on at of Consistent FDA am to DSMB to partial tolerability pancreatic agreed to for of care of clinical remain ductal events. cancer the current retinal clinical the the exclusion trial, review that trial ongoing focused continued administration abraxane Phase we used patients studies, from end, treatment monitoring in be recent pancreatic on the and retinal history the for for evaluating identifying agents in combination Panbela of with line which hold also in to of and recommendation an Panbela starting with we periodic update, SBP-XXX visual will independent the with highlights, quarter I adenocarcinoma. of in of metastatic risk the investigators adverse patients a first advancement with of standard SBP-XXX design nab-paclitaxel gemcitabine April, lifted or further first update the the in that future retinopathy safety So for and regarding the cancer, our SBP-XXX toxicity pending To We continuing finding provided additional that with I highlight detachment in dose hold. pleased and all the screening studies, include of included. ophthalmologists future patients was and

we excited of abstract announced April, the been Clinical XXXX SBP-XXX to an are held clinical has Also American of this With for Oncology partial that hold annual pancreatic Society forward. ASCO we presentation which be move efficacy Gastroesophageal, Cancer, in will virtually polyamine with with administered program signals session accepted first Pancreatic, treatment and with the in and June title as through from metastatic X, poster pancreatic SBP-XXX Hepatobiliary. The titled year inhibitor nab-paclitaxel This XXXX. subjects in will ductal is line Gastrointestinal for combination meeting, poster or cancer lifted, the the gemcitabine adenocarcinoma. a be number at showed X

available bit. forward After a gears at information publicly. to we on presenting poster information this our conferences.asco.org. ASCO can sharing at the look website. found be be Additional And will Shifting

response of To of the gastric and glioblastoma, and about cancer, explored. research with tumor the To broadened such we lines, polyamine Johns as best reiterate of remain and with suggests In partnership designed relationship announced we Published being across University to our activity between in cell increased and checkpoint program, clinical relationship others addition metabolism. the a School quarter, clinical driven ovarian mutation committed types the our SBP-XXX informing development The to inhibitors. breast, development including pancreatic addition colon, learn cell therapeutic pancreatic possibilities cancer, with with polyamine Hopkins program. in also the and lung, research also center to level biomarkers, diagnostics cancers, first immune agreement microenvironment, development potential around to expanding more are with combinations Medicine. how expand in is to implications, tumor

of these preclinical milestone. I this our efforts by the like would to point, expect year. We this yield in data At reiterating half will second finish

in new available randomized First, adjuvant to top Phase additional types this quarter. meeting And cancer ASCO A trial study of preclinical be the at milestones. year. secondly, data line trial annual will we in pancreatic I of in II other tumor investigation from represent second the and Phase plan a the the full middle initiate potential

inform first that literature have forward compound, in checkpoint and of metastatic we School University in our collaboration we've In to will future prospect important in year-to-date a addition across In of fact, be confirm effort. that lead pathways preclinical quarter moved expect our and again assumption combination the of is And we to yield ongoing will in Johns our also taken cancer. a under pancreatic the with summary, Medicine pursued this to lastly, indication second inhibitor work Hopkins that research with a development cancer, we steps data in preclinical pancreatic SBP-XXX great and the the half tumors is other year.

by continuing the provide commissioned expand increase beyond achieve I milestones we pancreatic our over releases news review plan Additionally, financials. cancer. will to uncovering value via addressable We're to our market and indications. Sue to to and to additional the the share this We these we have updates stop as to along research there and indication lead pursuing way. our turn and excited work in shareholder press

Susan Horvath

investigational change to costs our is of headcount General Jennifer. to expenses manufacturing compared DNO with the higher in The produce administrative to primarily March of incremental or Total development XXXX. quarter X.X X.X quarter quarter you, is and due other balance next expenses insurance in the quarter no of first as million X.X first There Total in date. of XX, X.X the assets debt was current due that first X.X in liabilities net XX. million clinical and of on were million loss increased X.X were we NASDAQ million was per cost million Net loss first product Research first were million cash the trial. million current XXXX. same quarter X.X Thank for the quarter the our XXXX. in also incremental and of million listing and The XXXX. X.X compared was in million, $X.XX were share XXXX first a XXXX, XXXX, to share, change diluted as compared March sheet as of diluted of associated of as premiums. X.X including the $X.XX of per or

common The stock outstanding table, XX.X million of fully a which insiders outstanding by includes held diluted stock million diluted to warrants we investors. purchase cap number were and the on to equity by are had awards, fully including common all Looking we options, shares basis XX.X and shares. at held

and the of net expiration. approximately outstanding During combination X.X exercise, cash through a the for cashless exercise by warrants million decreased quarter

other initiate please Our trial clinical concludes available XXXX. for the complete the you cancer and Q&A taking the my cash could for trial, prepared middle us current That lines in into believe questions? we indications randomized allow to Operator, dollars remarks. and adjust XXXX of us will poll open in preclinical phone

Operator

Yes.

a We will Please with Garner be Our Instructions] is conducting now proceed. [Operator question first question-and-answer Craig-Hallum. session. Robin from

Robin Garner

II Phase II congratulations pancreatic a on as questions and thank mid endpoints for a change think first you about that to might study to expect into this like I'd moving How we the my Phase taking Phase about year. from Hi, we programs start forward. I metastatic cancer would your the ask

Jennifer Simpson

Robin, evening? are this Hi, how you

Robin Garner

I'm doing great.

Jennifer Simpson

see drastically. Yeah, would the yet, that not have necessarily that so I I think finalized but the design endpoints changing we not

Looking think cancer primary it's really free comes I survival. - probably down endpoints response or to two at objective pancreatic progression rate either metastatic

we what finalize most we're sure design, an think endpoint So pursuing. we'll look that that we as to the make given I sense, makes that have

Robin Garner

like us And other that around a whether than that would have neoadjuvant past and Rather directly in curious you. done been about treatment, similar it, the the ask of thank to Okay, number endpoints total ask used, here? kind regarding if in studies you point the could to I'd question studies. sense of seen that what have space, been the of you've make neoadjuvant cycles study the designs that you

Jennifer Simpson

Sure.

outcomes. group versus it Folfirinox. So was I gemcitabine terms showed they of And in think helpful, study an use with that very no was neoadjuvant, proper study for or where SWAG looked was the us of abraxane the that because in and there at intergroup difference one space,

sense makes - So are gem that forward. in for moving combination what and since comfortable us we've is abraxane,

of but I'm find couple So others can I a that's that now, one. sure kind right certainly there's some. blanking

that be the and to response, complete long. of margins. looking endpoint, look by bit terms so have there hopefully quite with our make in was one surgery that In survival to be think - at would that's certainly certainly, pathologic because that chemotherapy followed of sure administering in have terms looking - like clean can one SBP-XXX case, I in That's patients, little conjunction following you things and a design at we endpoints the

of you So But that as incorporate give should we that of can be. idea be what easily. focus kind something would not the that may that brief a

Robin Garner

And you. talk looking a perhaps we SWAG see then expect you with without? about today at thank that to would can histological Okay, the versus typically great, that improvements study, neoadjuvant

Jennifer Simpson

back appropriately. to probably have look I to that answer to able would be

with So that's up you something could that. if okay, follow on I it's

Robin Garner

the studies? these of is course. much in for you partnership of there question and there. considering the around this and need about burn guidance Thank just the what and of you. the would additional terms I new begin studies totality, guess cash so in ramp how these they then you as thinking to But two the year? up two be expenses, Yes, especially And far, studies then will Thank final

Susan Horvath

see randomized in some the much the into us second then That half neoadjuvant, said assumptions up design conclude of Until of cost. with won't being until we leads have into the that won't later which lot second, to the ramp modeling, terms until the probably we guess of still of the the cash reluctant Sure. have us increase I'm kind really that total to trial into will really XXXX. and year. begin first into last built something a we cash Trials the full to

Robin Garner

And Congratulations you continuing Thank great. we're again, ASCO and partnership this updates any so Okay, programs. Thank the the later pretty much. from you. the see to excited on at additional data year.

Susan Horvath

Thank you, Robin.

Operator

and session. question-and-answer end reached Ladies we you. the end And conference. gentlemen, of today's will the Thank have this

at much time. you lines a have day. this and your disconnect Thank participation may very You your for great

Panbela Therapeutics (PBLA) 13 May 212021 Q1 Earnings call transcript